{"ticker": {"uuid": "3a953705-10d5-42ca-92f3-2c3c0dcfa50a", "symbol": "6996", "name": "Antengene Corporation Limited", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-07-13T04:16:10+00:00", "published_display": "13 Jul 2026 04:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Corporation Limited commences an Equity Buyback Plan for 67,924,413 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2026.", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgJBVV95cUxOcDM4c2taZ0phR3NSVW8yTUp4cmhxYWJPM3B5NDBjQy03RzMyWGxBZzYyUWhRMTllRzRpQ0hVOFowZ3M3bWpHcVVIM2pib2diQmFydHZPT25Vb2lKZTVkN28xZmp5RUliMWJ1bXJ1TlhDRXJsUzJPV2ZmbDhWTHNRckR0QWo1VUJBT2lTRHJ0dHQ0bXN5ZGV4dWo4bmFKa09HZnFmWjBmUG1naVJVTjF6R0pNSktpdUZrdWhrSllrOUhPVl9LcW1KLS1KWWx4bFNUUjBicE9GemwyV2Q5a2ZraURicHRWVDlUbGNHZVlrV0lTMzRwUXhYNlpKcFhWZlAtVEZCZmh1eU9UNExUd0pRTGhVQWM0U2pNMHJXOXZxaGxNZTJTendyMGlGZkVmUQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-09T12:15:00+00:00", "published_display": "09 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "K2 nabs two Antengene bispecific TCEs in $2B license, option deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOZG9FRkNuU0JEZlRlTXZtR1FRWFJveGZ3RXBMSk1kRDlwQXY2UzJMbjdfR2VCMWtaZ3BzcUJ0YUpVOGR5NnFraEJhSlpFYlgySkVERXhRM19PQXBDSm9ub0s5RlEtdlVQSkFTbll4UzVxVUpxRWgyT251ZTA3TmE1NjlkNDEySmwxRUxha2NNNVZmcHlGdDg2NHR4ekN3eFpGVGlNRkNlYw?oc=5", "source_name": "BioWorld News", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQYW5fNUpuSFNYLUZmSFpkS2hOVXVIT0o5MmRkMGR3cENTYzRpY3RzZmVMbFZCZFhUaGhKTWQ1ZTFMV2JrUGRZZktzeF9qQk9leUctRTJzTXlOeDIxY19RdXRtTUlWblV4VXZxU1k0WDhveGxscVpUeUVEQWJyYmJ2ckd0WktHSDQ0YjNSRXIzN05TaHdWa0lCek5iOC1oZ040Xy1YZmFsdGNGZEVXeERxVXRoeGZFRTJaV3hVZy1B?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T00:42:07+00:00", "published_display": "22 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOV1VZNUx1ZDh5bGJMeklqek9XSThpQmM5cHh6bVpLM1gwLUViLWR0Mk1XX2FWUngzUEVjWXVoRDFESEhSOUZBX0hUTDBSdEZ2SnJDMFhYeVFodU5IcVVjUHdRUlJaWXoxSmhjNGt0LWp3dktCdTdUNV9oN0x2NkFSaFZIaWpXbFlUWjRsQU5NdlE3bGlwdUI5U3kzNk1pdXRzellKcEs5TDFKa25ZQjZwdE95QWpvbUZRbm55Y1k2MTFZdG4yVWFpSDZzOHljcGQ5Nl9TZmdQbGJ5bHpGUjJObkJQUXVESFVoMjlrRzd3WHZJV2RpNElkMUtzRHpnODBCQjZCSkFoRG81UUdJaW5fVDBleFNVX1k?oc=5", "source_name": "BioSpace", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Receives IND Approval for ATG-201 (CD19 \u00d7 CD3 TCE) in Autoimmune Disease in China", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UCB inks $1.1B deal for Antengene\u2019s autoimmune bispecific TCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UCB boards T cell engager train in $60M upfront deal with Antengene", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNel9IeE91Z05WT2VaSWhOWGltaEZSOG9KYWhya1hHTGhpekxhYVFSZ3lsT1lxY3czUHUtSzIxN2JWSzFPV1BMcXhJd3lNVjAxQmYydldXM3A4NkpZd1VDRUpaS19Ec19ScG01dlhXbDlxVm1XSDN1cmNCQUpfM2hEY1RpOEtzSWZqalVaVmZBTFlGMkhj?oc=5", "source_name": "Endpoints News", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA\u00ae (pembrolizumab)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxPRExzQ2twOFRNODhoSlRQV0tmejhOR3FhUnlPaGhTNkNkSHZteFJaOUpJMGNrUWtiZ2V3Z050MThsMThXcFpyeVFnVk5aYXdaamFCNFRRbWtSUUozbnRULTNqRFpmaFNGTm1GTXRZZm1JdXZFVWRwYnVIbExVVE5Wczh3Ym9BMWcycTVfTW5fUklKYnVKRUVfSEhFaEdHYlVjODRTOWhsUFJ6WVdKazdOYUtFUTBiRTFJdHA5cmtWcmRrdV9TN1Y2TzlSUVBhaEVzdkRaLUx3dmtxZU1EYVYzUlY5Q0V2YWNnNk9SdldNbmlfNFRUQm9TeWNsbl9QaFVDcy1mTV9JbXo0UQ?oc=5", "source_name": "BioSpace", "published_at": "2025-05-20T07:00:00+00:00", "published_display": "20 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Announces XPOVIO? (selinexor) Approved for Commercialization in Malaysia", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFBXNk9zNk5HNDJkNlV3RG5sczdfcjhGbmFBcFdsODktZnk0Y25QejZ0VlJScXZmcGg3dHNSQ2txcjRJQzdBZllzRnVTLVBXNWpNaWt1OVdiZXNBY1hCSlY0YnAzUUZvMjNo?oc=5", "source_name": "aap.com.au", "published_at": "2024-08-06T07:00:00+00:00", "published_display": "06 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9DVTg2NXp5Q3ktUERtUVdRLWxmUDFHVzU4V0tJdE9ndFV6bU1vTVliZF9NRklfemhzeVRDVk9IRVRkTWUxRHR6NzdzUGJJNjZmVzJSeFZpU2hVLVA4cWM1MUVvNnpOQQ?oc=5", "source_name": "The Pharma Letter", "published_at": "2024-07-06T16:53:45+00:00", "published_display": "06 Jul 2024 16:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANTENGENE CORPORATION LTD. - B (6996)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQSTZxNThzSU5nTzl6WEhuYlhLQ29uWldSZlFRakRRSVN0WEhFTHlwai1RTmt6UkNXZURBM2txNnJkbXoxdHRnVlgyeUxIejQyeWlRaHJzLXpSMThDVjBhUE1uWUR6dE1BSkQ1WTY0c2F0WW5UR2VjbTVmT2NodFUtb1J1bW9SbmhGVEh1Q1V0cDF2ckJuaDBKM3pYNDBtZw?oc=5", "source_name": "hkex.com.hk", "published_at": "2020-11-20T08:00:00+00:00", "published_display": "20 Nov 2020 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-07-13T04:16:10+00:00", "published_display": "13 Jul 2026 04:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Corporation Limited commences an Equity Buyback Plan for 67,924,413 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2026.", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgJBVV95cUxOcDM4c2taZ0phR3NSVW8yTUp4cmhxYWJPM3B5NDBjQy03RzMyWGxBZzYyUWhRMTllRzRpQ0hVOFowZ3M3bWpHcVVIM2pib2diQmFydHZPT25Vb2lKZTVkN28xZmp5RUliMWJ1bXJ1TlhDRXJsUzJPV2ZmbDhWTHNRckR0QWo1VUJBT2lTRHJ0dHQ0bXN5ZGV4dWo4bmFKa09HZnFmWjBmUG1naVJVTjF6R0pNSktpdUZrdWhrSllrOUhPVl9LcW1KLS1KWWx4bFNUUjBicE9GemwyV2Q5a2ZraURicHRWVDlUbGNHZVlrV0lTMzRwUXhYNlpKcFhWZlAtVEZCZmh1eU9UNExUd0pRTGhVQWM0U2pNMHJXOXZxaGxNZTJTendyMGlGZkVmUQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-09T12:15:00+00:00", "published_display": "09 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "K2 nabs two Antengene bispecific TCEs in $2B license, option deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOZG9FRkNuU0JEZlRlTXZtR1FRWFJveGZ3RXBMSk1kRDlwQXY2UzJMbjdfR2VCMWtaZ3BzcUJ0YUpVOGR5NnFraEJhSlpFYlgySkVERXhRM19PQXBDSm9ub0s5RlEtdlVQSkFTbll4UzVxVUpxRWgyT251ZTA3TmE1NjlkNDEySmwxRUxha2NNNVZmcHlGdDg2NHR4ekN3eFpGVGlNRkNlYw?oc=5", "source_name": "BioWorld News", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene licenses ATG-106 to K2 Therapeutics for $20M upfront", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQYW5fNUpuSFNYLUZmSFpkS2hOVXVIT0o5MmRkMGR3cENTYzRpY3RzZmVMbFZCZFhUaGhKTWQ1ZTFMV2JrUGRZZktzeF9qQk9leUctRTJzTXlOeDIxY19RdXRtTUlWblV4VXZxU1k0WDhveGxscVpUeUVEQWJyYmJ2ckd0WktHSDQ0YjNSRXIzN05TaHdWa0lCek5iOC1oZ040Xy1YZmFsdGNGZEVXeERxVXRoeGZFRTJaV3hVZy1B?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T00:42:07+00:00", "published_display": "22 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOV1VZNUx1ZDh5bGJMeklqek9XSThpQmM5cHh6bVpLM1gwLUViLWR0Mk1XX2FWUngzUEVjWXVoRDFESEhSOUZBX0hUTDBSdEZ2SnJDMFhYeVFodU5IcVVjUHdRUlJaWXoxSmhjNGt0LWp3dktCdTdUNV9oN0x2NkFSaFZIaWpXbFlUWjRsQU5NdlE3bGlwdUI5U3kzNk1pdXRzellKcEs5TDFKa25ZQjZwdE95QWpvbUZRbm55Y1k2MTFZdG4yVWFpSDZzOHljcGQ5Nl9TZmdQbGJ5bHpGUjJObkJQUXVESFVoMjlrRzd3WHZJV2RpNElkMUtzRHpnODBCQjZCSkFoRG81UUdJaW5fVDBleFNVX1k?oc=5", "source_name": "BioSpace", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Receives IND Approval for ATG-201 (CD19 \u00d7 CD3 TCE) in Autoimmune Disease in China", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UCB inks $1.1B deal for Antengene\u2019s autoimmune bispecific TCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UCB boards T cell engager train in $60M upfront deal with Antengene", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNel9IeE91Z05WT2VaSWhOWGltaEZSOG9KYWhya1hHTGhpekxhYVFSZ3lsT1lxY3czUHUtSzIxN2JWSzFPV1BMcXhJd3lNVjAxQmYydldXM3A4NkpZd1VDRUpaS19Ec19ScG01dlhXbDlxVm1XSDN1cmNCQUpfM2hEY1RpOEtzSWZqalVaVmZBTFlGMkhj?oc=5", "source_name": "Endpoints News", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA\u00ae (pembrolizumab)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxPRExzQ2twOFRNODhoSlRQV0tmejhOR3FhUnlPaGhTNkNkSHZteFJaOUpJMGNrUWtiZ2V3Z050MThsMThXcFpyeVFnVk5aYXdaamFCNFRRbWtSUUozbnRULTNqRFpmaFNGTm1GTXRZZm1JdXZFVWRwYnVIbExVVE5Wczh3Ym9BMWcycTVfTW5fUklKYnVKRUVfSEhFaEdHYlVjODRTOWhsUFJ6WVdKazdOYUtFUTBiRTFJdHA5cmtWcmRrdV9TN1Y2TzlSUVBhaEVzdkRaLUx3dmtxZU1EYVYzUlY5Q0V2YWNnNk9SdldNbmlfNFRUQm9TeWNsbl9QaFVDcy1mTV9JbXo0UQ?oc=5", "source_name": "BioSpace", "published_at": "2025-05-20T07:00:00+00:00", "published_display": "20 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene Announces XPOVIO? (selinexor) Approved for Commercialization in Malaysia", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFBXNk9zNk5HNDJkNlV3RG5sczdfcjhGbmFBcFdsODktZnk0Y25QejZ0VlJScXZmcGg3dHNSQ2txcjRJQzdBZllzRnVTLVBXNWpNaWt1OVdiZXNBY1hCSlY0YnAzUUZvMjNo?oc=5", "source_name": "aap.com.au", "published_at": "2024-08-06T07:00:00+00:00", "published_display": "06 Aug 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antengene", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9DVTg2NXp5Q3ktUERtUVdRLWxmUDFHVzU4V0tJdE9ndFV6bU1vTVliZF9NRklfemhzeVRDVk9IRVRkTWUxRHR6NzdzUGJJNjZmVzJSeFZpU2hVLVA4cWM1MUVvNnpOQQ?oc=5", "source_name": "The Pharma Letter", "published_at": "2024-07-06T16:53:45+00:00", "published_display": "06 Jul 2024 16:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANTENGENE CORPORATION LTD. - B (6996)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQSTZxNThzSU5nTzl6WEhuYlhLQ29uWldSZlFRakRRSVN0WEhFTHlwai1RTmt6UkNXZURBM2txNnJkbXoxdHRnVlgyeUxIejQyeWlRaHJzLXpSMThDVjBhUE1uWUR6dE1BSkQ1WTY0c2F0WW5UR2VjbTVmT2NodFUtb1J1bW9SbmhGVEh1Q1V0cDF2ckJuaDBKM3pYNDBtZw?oc=5", "source_name": "hkex.com.hk", "published_at": "2020-11-20T08:00:00+00:00", "published_display": "20 Nov 2020 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 82, "total_relevant": 13, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 13, "score": 50, "total": 13, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 3.85, "count": 7}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 4.27, "latest_week": "2026-07-10", "one_week_move": -1.2, "four_week_move": 19.6, "twelve_week_move": -28.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.720762, "market_dynamics_buy_signal": false, "relative_strength": -4.54564, "fair_value_gap": 65.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 39.0171, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.2% over one week, +19.6% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "The Manila Times", "count": 3}, {"label": "BioWorld News", "count": 2}, {"label": "BioSpace", "count": 2}, {"label": "marketscreener.com", "count": 1}, {"label": "Investing.com Nigeria", "count": 1}, {"label": "Endpoints News", "count": 1}, {"label": "aap.com.au", "count": 1}, {"label": "The Pharma Letter", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 13}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 7}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "13", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.2% over one week, +19.6% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB"}], "updated_at": "2026-07-18T00:19:46.692447+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}